Navigation Links
Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
Date:10/11/2010

MISSISSAUGA, Ontario, Oct. 11 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.  Valeant's subsidiary, Biovail Laboratories International SRL (BLS), entered into a collaboration and license agreement with Alexza Pharmaceuticals, Inc. in February 2010 for the U.S. and Canadian rights to commercialize AZ-004.  AZ-004 is being developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.  

A CRL is issued by the FDA's Center of Drug Evaluation and Research indicating that the NDA review cycle is complete and that the application is not ready for approval.  In the CRL received by Alexza, the FDA stated that their primary clinical safety concern was related to data from three Phase I pulmonary safety studies with AZ-004.  This concern was based on observed, dose-related post-dose decreases in forced expiratory volume in one second, or FEV1, a standard measure of lung function, in healthy subjects, and in subjects with chronic obstructive pulmonary disease (COPD) and asthma.  Alexza intends to meet with the FDA in the near future to discuss steps necessary to address this FDA concern.  Alexza has previously reported that there were no serious or severe respiratory adverse events in these trials or reported in the two Phase III clinical trials of AZ-004.  All respiratory symptoms that developed after treatment in Phase I subjects with COPD and asthma were eit
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Unchained Labs, a refreshingly new biologic tools ... conference and launches the UNit — the first and ... Essential Protein Engineering Summit takes place in ... UNit lets drug discovery researchers look at more protein ... 7 applications, 144 sample a day throughput and 9 microliter sample ...
(Date:5/4/2015)... May 4, 2015 Intarcia Therapeutics, ... Michael Williams into the newly created role ... a senior pharmaceutical executive with world-class experience – ... and distinguished service at industry leaders such as ... a broad range of therapeutic areas, including: cardiovascular, ...
(Date:5/4/2015)... N.J. , May 4, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... multiple countries worldwide, will report Q1 2015 financial ... 11, 2015.  CytoSorbents, management will ... that will recount both operational and financial progress ...
Breaking Medicine Technology:Unchained Labs Lets the UNit Loose 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3
... Inhibitex, Inc. (Nasdaq: INHX ) today announced that ... its common stock, at a purchase price of $4.10 per ... proceeds to Inhibitex from the sale of the shares, after ... to be approximately $44 million.  Inhibitex has granted the underwriters ...
... Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTCBB: ... Company,s therapeutic and preventative HIV vaccines at the 2011 World ... in Washington DC on Thursday, April 14.  Dr. Robinson,s invited ... cover the topic of recombinant viruses as vaccines. The talk ...
Cached Medicine Technology:Inhibitex Prices $47 Million Public Offering 2Inhibitex Prices $47 Million Public Offering 3GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress 2GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress 3
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... New West Medicare is excited to ... to manage outpatient advanced imaging services for its members. ... its members are provided the right test at the ... with New West Medicare’s physicians and hospitals, Care to ... advanced imaging and provide an objective basis for informed ...
(Date:5/4/2015)... Sylvia Hawthorn-Deppen shared her experiences living with ... others in similar situations that they were not alone, in ... Discovery of New Energy” (published by Balboa Press). This year ... renewed press campaign. , “I have spent nearly 60 years ... says. “As an adolescent I got into trouble with an ...
(Date:5/4/2015)... Fast on the heels of Autism Awareness ... Allison Folmar, JD, join over 150 speakers in the ... Sunday, May 24, the conference presents "I Know You're ... interested in Ryan Hinds' recovery story? The book ... autism was written by Marcia Hinds, Ryan’s mom. ...
(Date:5/4/2015)... Sara Soulati, CEO of Global Cardio ... Los Angeles associated with the field of Enhanced External ... Sara Soulati Health For Life Program (SSHFLP). , The ... modification and disease prevention program. A provisional patent ... Patents and Trademarks Office and is now under review ...
Breaking Medicine News(10 mins):Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... chemically-modified version of a mitochondrial toxin long used to ... found to selectively inhibit two "survival proteins in ... step toward developing a molecularly-targeted drug that could eliminate ... therapy found in many types of cancers. ,scientists ...
... just how important it is for mothers-to-be to relax, by ... their offspring will develop cerebral palsy . ,Cerebral ... disability. ,Though the study was conducted on a ... sante et de la recherche medicale, the French public biomedical ...
... together to plug the site of injury in the form ... aggregation can block blood vessels and cause heart attack ... many molecules to platelet integrin alpha-IIb beta 3, and blockade ... clots. ,However, chronic use of oral drugs that ...
... for neuroblastoma that lands a one-two punch works best when ... of the first one, according to results of studies at ... tumor that arises from cells in the peripheral nervous system. ... by using the drug bevacizumab to block VEGF, a protein ...
... tobacco industrys deceptive practices have been aggressively quashed through ... Ibrahim , co-author of an analysis in the August ... ,In the article, Ibrahim tracks the rise and ... for the past 40 years. She chronicles industry strategies ...
... the long-standing claim that organic farming methods cannot produce ... can yield up to three times as much food ... on the same land. ,Researchers from the ... were almost equal on organic and conventional farms. ...
Cached Medicine News:Health News:Cell Toxin Inhibits Survival Protein in Cancer Cells 2Health News:Tumor Blood Flow can Improve Chemotherapy 2Health News:Tumor Blood Flow can Improve Chemotherapy 3Health News:Tobacco Industry Promotes Antismoking Campaigns 2Health News:Tobacco Industry Promotes Antismoking Campaigns 3Health News:Organic Farming can Feed the World, U-M Study Shows 2Health News:Organic Farming can Feed the World, U-M Study Shows 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: